Amplicons of chromosome 11q containing of FGF19, an exclusive ligand of FGFR4 activating MAPK and JNK signaling in hepatocytes,38,39 have been reported in CCA.40 FGF19 amplification has been proposed as a predictive biomarker for sorafenib response in hepatocelluar carcinoma (HCC),41 despite a lack of relevant FGFR inhibition by sorafenib, suggesting relevance of downstream sorafenib inhibition of RAF1/BRAF in this context. Here, FGF19 is linked to hepatocellular carcinoma.